BYL719 has been shown to be also clinically effective in adult patients with PIK3CA-related overgrowth syndrome (PROS) and children under 1 year of age (Madsen and Semple, 2022; Morin et al., 2022). Here, PIK3CA is linked to overgrowth syndrome.